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Discussion Following the Remarks of
Minister Michel C6t6
and Dr. Harvey Bale
QUESTION, Professor King: I want to ask Minister C6t6 a question
about the updating of the copyright and patent laws in Canada. It seems
to me that you are updating these in light of new technology, such as
computer programs, semiconductor chips, and biotechnology. However,
I am sure there will be other future developments. Do you visualize any-
thing further than the changes you have mentioned to take care of these
other technological changes? How do you parallel patent and trademark
laws with the changing context of technology? You can update it as of
now, but what of the future? Should there be some collaboration be-
tween the United States and Canada on that issue?
ANSWER, Minister Cdt6: To begin with, we made important
changes when we came into power in September of 1984. We amended,
for instance, the old Foreign Investment Review Act that now is being
called Investment Canada. Along with that, we had to make some other
important steps which relate to intellectual property and are very impor-
tant to Canada. We have already amended our Combines legislation, for
instance, to enhance competition.
Last December we introduced a new competition act, but we also
want to deal with the intellectual property. In this area we have an-
nounced our intention to do something with the amendments of the Pat-
ent Act and, especially, regulations related to the pharmaceutical
industry. We know how it is important to our trade partners to receive
the signal that Canada is prepared to change and to bring major change.
One of the major items that we have in mind is to make sure that we
protect the intellectual property which, for instance, in the pharmaceuti-
cal sector, we are not doing with the present compulsory license law that
has been in force since 1969.
There is important change to bring. On the copyright side, we have
received a lot of recommendations from our country. We not only want
to bring the laws up-to-date, but we also want a flexibility in the laws
allowing for quick readjustments to new technologies and new innova-
tions, both in the country and in the world.
Once again, it is important for us to have our trade partners receive
a very unique signal that Canada is ready to make the necessary steps to
welcome free enterprise and to create investment, as well. This will allow
for better commercial activity, both for Canada and our partners.
QUESTION, Professor King: I have one question for Harvey Bale.
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In terms of the actual details of the trade agreement, which you are not
obviously going to discuss in detail, do you want to list any specifics that
might be included in a trade agreement with Canada in this area of intel-
lectual property?
ANSWER, Dr. Bale: Forecasting is a very difficult business. The
issue, as Minister C6t6 has mentioned, has been raised at the heads of
state level and the issues that have already been mentioned would cer-
tainly be matters that need to be addressed soon.
Now, to the extent that the two countries believe that intellectual
property protection is intrinsically worthwhile to adopt for their own
reasons, for trade reasons, or for competitive reasons, this should be done
independent of a formal negotiation. My expectation is that before we
arrive at a trade agreement of a comprehensive nature, which I hope we
do, we will have addressed many, if not most, of the matters in the intel-
lectual property field on both sides. Presently, there are continuing con-
sultations between the patent and trademark experts. These are issues
between our two countries that can be dealt with fairly quickly since we
do, to a considerable extent, share common goals. Some of these issues
involve considerable lost copyright and patent holdings where damages
are involved. In these cases, there is a related point that is at stake: the
U.S. belief that such practices come under the category of an unfair trade
practice where concessions should not be exchanged to see their removal.
Instead, the U.S. believes that we should urge, as in the cases of Korea
and Brazil, informal section 301 proceedings, where bilateral discussions
between our two countries would resolve these problems.
QUESTION, Professor King: In connection with some of the coun-
tries that you are mentioning, to pursue multilaterally may be a problem
because they are not members of GATT. Does that pose a problem?
ANSWER, Dr. Bale: Many of the countries that are problem coun-
tries, such as Singapore, Korea, Malaysia, Indonesia, Egypt, Brazil, Mex-
ico and others, are oftentimes members of GATT in this area, but not
members of a major intellectual property institution, such as the Paris
Convention, the Berne Convention or the UCC. I think that there is a
problem of membership, but I don't believe it is a significant problem.
There is a problem, however, in getting developing countries to adhere to
stronger international intellectual property protection rules. That is a
problem which exists now in the discussions under the Paris Convention,
the Berne Convention, and other conventions. Of course, the United
States is not a member of the Berne Convention, which is another prob-
lem, I'm sure, that should receive some discussion today. The Adminis-
tration has made a decision to pursue that adherence.
I would also like to point out a policy statement that may be of
interest. It was issued on April 7th and addressed this question of multi-
lateral rules. Also addressed were objective standards that need im-
provement and a legislative package that was issued on that same date.
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QUESTION, Professor King: Minister Crt6, addressing the subject
of pharmaceuticals, I have spoken with some of the pharmaceutical com-
panies in connection with the planning of this conference and they ex-
pressed a concern about the 4% royalty and the compulsory licensing
provision. These companies feel that a 4% royalty for pharmaceuticals
does not pay for the research. Would you please comment on what the
Canadian government says?
ANSWER, Minister Cdtd: As I previously said, the compulsory li-
cense has been working since 1969 from the preceding government. The
objective when they put that system in place was to lower drug prices in
Canada because at that time Canada was the third country to pay the
highest drug prices. But by doing that, Canada was becoming probably
the only industrialized country to control drug prices by addressing the
intellectual property.
In 1981 and 1982, the former government believed that it was time
to re-examine the situation and they created, in April of 1984, a commis-
sion to review the whole compulsory license system and make recom-
mendations. Dr. Eastman chaired this commission and he presented
some recommendations in May of 1985. His recommendation, for the
most part, was to give protection, or a period of exclusivity, to the phar-
maceutical industry for four years and increase the royalties from 4 to
14%. We have examined these recommendations, but we believe that
Mr. Eastman is not going far enough.
The Mulroney government believes that the pharmaceutical indus-
try needs to receive better protection in order to create the investment
and jobs and initiatives that we need in this country. Therefore, the
changes that we are working to bring will extend that period of
exclusivity.
We, as well, want to make sure that the benefit to Canada will come
in terms of investment and the creation of jobs and we are dealing with
the industry in order for that to happen. However, we have to face a
very important political issue. As you know, each province in Canada
has a Medicare plan and is paying for the drugs that the senior citizens
and welfare recipients are using. So the provinces know that if we have
to extend that period of exclusivity, increasing, to a certain extent, the
drug prices, these increases will be transferred to the provinces. There-
fore, we have to face some political reaction.
On top of that, you also have the insurance companies that if they
have to pay or reimburse higher drug prices to their clients. It is that
kind of political environment that we have in Canada, but, I think that
we are just about ready to make our move. I would say that it's imminent
and will be in this area.
Furthermore, we want to make sure that the investment will come
in to Canada and we are ready to give the needed protection. Therefore,
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we will put in place the mechanism allowing us to monitor or watch the
evolution of these drug prices.
QUESTION, Mr. Wolfe: I have a question for Mr. Bale. I have
read the April 7th statement. I think you stated the notion of using trade
statutes for intellectual property goals more clearly than we understood
it.
To take a specific example, you are working with § 337. I wonder if
trade policy in the case of § 337 is well suited to what you are trying to
do. Although I steal my ideas here a bit from the trade bar in Washing-
ton, I wonder if what you are trying to do goes in the direction of using
trade policy, not simply to enforce the right, but to establish a right. Is
the ITC well suited to doing that? Does that take trade policy in direc-
tions to which it is not well suited? Does it take us even farther away,
stating Canadian bias here, from national treatment with § 337?
ANSWER, Dr. Bale: I have testified on it before a couple of judici-
ary committees in the Senate and the House. The question of using a
trade statute to protect intellectual property has been there for some
time. From the proposals that have been made, the question is whether
or not improvements can be made to the trade statute in order to im-
prove the protection of intellectual property; or stated another way, are
certain aspects of current laws inadequate or not up-to-date to protect
intellectual property in the United States? We believe that's the case and,
in some cases, our proposals would extend the use of § 337 to foreign
nationals. Some questions have been voiced on that issue. In particular,
one of the commissioners of the ITC, the current chairperson, questioned
the use of extending the protection of U.S. trade statutes to foreign na-
tionals. However, where the United States registers a patent and grants
it protection, we think it appropriate to provide protection of U.S. laws
through an extended use of § 337. I would argue in that sense that we
are moving toward national treatment, but we would also like to reduce
the uncertainties and the costs and broaden the coverage of intellectual
property protection by changing a number of laws, including this one.
This is not the only statute where change is being considered. We
would also like to extend our protection to process-patent holders under
existing patent laws, which is presently unavailable, through a proposal
that we have in the process-patent field. It has to be looked at in terms of
a package.
QUESTION, Mr. O'Flaherty: I have a question for Minister C6t6,
which relates also to § 41, but the other aspect of § 41 which you haven't
commented on. Section 41 also provides that food products are not pat-
entable in Canada, and to the extent that patent protection can be ob-
tained, they are subject to compulsory license. That was a part of the
statute that was taken over from the British and, subsequently, the Brit-
ish rescinded their law. The Canadians, however, kept theirs. It has not
been a part of the statute that has been used too often- maybe three or
four times in its existence. It could, however, have very serious conse-
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quences to people that might be caught up under the Food Product Com-
pulsory Licensing Act. I know that about a year ago you received a
number of submissions suggesting that that part of the statute be re-
scinded. Could you comment on what you are planning to do about
that?
ANSWER, Minister Cdtd: We are just re-examining the whole situa-
tion in that context. We have some plans in mind. As I said before, the
whole revision of the patent act will happen.
We are dealing now with the pharmaceutical area because it is a
more sensitive issue and, I might add, it has become a matter of intense
discussion between the United States and Canada. But, I have no doubt
that on your point we are also looking to bring up some amendments and
some changes.
QUESTION, Mr. Plaia: I have a question for Dr. Bale concerning
the amendments to § 337. Is it your latest proposal to eliminate only the
injury aspects of the statute and retain the industry requirement?
ANSWER, Dr. Bale: No.
QUESTION, Mr. Plaia: If that is so, do you support eliminating
the injury alone, without eliminating the industry?
ANSWER, Dr. Bale: The Administration's proposal is to eliminate
the injury based upon certain principles noted in some GATT cases, the
desire to broaden the coverage of protection, and the desire to eliminate
several aspects of the § 337 criteria with respect to copyright, patent, and
trademark protection. It's not a more general change to § 337 but with
regard to these types of infringement cases, our proposal would eliminate
the injury test. It would also eliminate the industry test.
QUESTION, Mr. Plaia: If legislation were passed through the
House of Representatives which eliminated injury, but not industry,
would the Administration still support that proposal?
ANSWER, Dr. Bale: We would have to look at that. At present we
have no position on that.
QUESTION, Mr. Knopf: Dr. Bale, I wonder if you have anything
to say about the timing and status of the long-awaited announcement on
Gray Marketing parallel importing?
ANSWER, Dr. Bale: The ITC recommended to the Administra-
tion, when the so-called "Duracell Battery" case came up for review, that
Gray Market imports of these batteries be excluded. The Administration
stood on long-term policy grounds to restrict those imports.
There is a review under way in the Administration, again, however,
of the Gray Market issue. One could argue that it is, perhaps, "too little,
too late," because one of the primary motivations of Gray Market im-
ports was the over-valued dollar. Now, perhaps, our dollar is over-val-
ued with respect to the Canadian dollar.
In a general sense, the incidence of Gray Market imports, I think,
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has diminished. At least we haven't heard about them in Washington as
much as we had over the last several years.
Nevertheless, the long-term issue of Gray Market imports continues
to be there. Moreover, by saying that that's a problem, I'm giving you
my perspective, which is one that is not shared by some in the
Administration.
The principle on which the basic policy has been founded is that
Gray Market imports are a pro-competitive force. Nonetheless, certain
options are being considered, which, at this point, are a little bit too early
to discuss. However, I do not see a radical departure from our Gray
Market policy in the pending developments of court proceedings pres-
ently underway.
The questions that are being discussed are a means of, perhaps, bet-
ter identifying Gray Market products from a consumer point of view.
Therefore, because there is this consumer interest, as well as the pro-
competitive interest, it is my view that we need to better balance those
interests.
COMMENT, Mr. Jackson: Mr. Bale said that the consumer interest
in the United States regarding free trade was not an effective force, while
consumer interest in Canada is a very important aspect of the § 41 phar-
maceutical drug price question. At the same time, I think top manage-
ment interests are very important too.
I have worked for a couple of national corporations. I have seen one
which has a deliberate policy of encouraging independent decision-mak-
ing and research in countries other than the United States, and another
one where all decisions were made at the head office in the United States.
Patenting was all integrated in the head office and research in other coun-
tries was either limited, discouraged or treated with a sort of, "we are not
really very interested unless this is useful in the United States" attitude.
Now, when we are talking about changes in industrial and intellec-
tual property laws, we should think about the trade off between con-
sumer interests and local interest, in countries where affiliates operate, as
well as the centralized management policies and interests in the United
States and other highly industrialized countries where the patents
originate.
COMMENT, Minister Citd: That is exactly the debate that we have
in Canada because, as Mr. Jackson has said, we have to keep in mind the
consumers' interest. For instance, Eastman's Commission has examined
thirty-two drugs that were sold in Canada. They compared the prices
between the pharmaceutical industry prices and the generic prices and
the prices that were paid in the United States. You could end up with a
savings of $211 million.
That's only on thirty-two drugs. That shows you that if we bring a
change in Canada in order to protect intellectual property, consumers
will have to pay higher prices somewhere. If they don't they won't get
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the savings that they should have gotten. Those are the concerns that we
as politicians have.
That's good to have a philosophy to protect the intellectual property
and make sure that we create investment and that we create an environ-
ment to bring in research and development. For instance, in Canada,
there are over $2 billion worth of drugs sold in the country.
It only represents, probably, 3 to 5% of all of the drugs sold in the
world. That shows you how little it is. On the other end, if we want to
bring changes, we can do it, but we want to make sure that research will
be spent in this country. In Canada right now the pharmaceutical indus-
try is only spending a little over 4%, in terms of sales volume, for
research.
They are spending 4% on research, and yet it's not fundamental
research. Most of it is clinical research. We want to make sure that
when we bring changes, we will have that kind of commitment from the
industry.
We believe in it. We believe it is important to protect intellectual
property, but on the other end, it is important to protect the consumers'
interest. We have to keep the consumer in mind.
QUESTION, Mr. Duvall: I have an intellectual property protection
question for Dr. Bale and perhaps Minister C8t6 would care to comment
well.
It is my understanding that the Reagan Administration is support-
ing a regional patent office for the western hemisphere comparable to the
European Patent Office. It is my understanding that this ties into the
patent cooperation convention which a few Latin American countries
are, at least, members of. In view of your statement about the nonpar-
ticipation of many countries in these patent conventions, I was wonder-
ing if you could give us the status of that initiative and what you see as
the outlook for it. I assume Canada is also involved in it.
ANSWER, Minister Ct6: I just want to say, if it is true, we would
like to have it in Canada. There have been only very informal discus-
sions of this idea. It has a certain political sensitivity involving questions
of "what" and "where," "how" and "how fast," and "what is involved in
it?" This also appears in our April 7th statement in more general terms
than it has appeared in certain public documents before. We referred to
the desirability of multilateral or regional participation, without neces-
sarily specifying the regions. It is a concept that is worth exploring, but
it has to be done in a way that will likely yield some real benefits and not
raise concerns on anybody's part.
QUESTION, Mr. Wright: I've been trying to restrain myself from
getting up because I think what I'm about to say isn't going to be too
popular among some of the people here. As an industrial property litiga-
tion lawyer, I sincerely hope the government does restore the full patent
protection to pharmaceuticals. We haven't had much interesting phar-
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maceutical litigation for quite a few years. I'm getting quite excited
about the prospects.
On the other hand, representing the consumer, or the public inter-
est, I have never been able to understand why we have to jump out of the
frying pan and into the fire, so to speak. I don't see why we necessarily
have to go from something that most of the pharaceutical companies
think it is too low of a royalty, to a sudden restoration of patent
protection.
If the act was applied as it was supposed to be applied, and a reason-
able royalty was awarded, how can anybody complain? It seems to me
that the thrust ought to be directed to whether the government thinks a
reasonable royalty is not being awarded.
I can see the Minister's position. He's trying to balance the interest
of the pharmaceutical companies, on the one hand, and the consumer
interest on the other. Surely that's exactly what § 41 was designed to do.
Why can't you do that in the way that you determine the compensation
to the pharmaceutical companies for their industrial property rights,
rather than saying the only things that we can do is restore the patent
rights?
ANSWER, Minister Ct6: I think that I have explained the prob-
lem. We are politicians. We have to make sure that we want to be here
five years from now. We have to make the good decision and sound
decision.
We think that in order to provide intellectual property protection
we must amend the Patent Act-especially § 41. Primarily we feel this is
needed so that the industry can create investment and jobs. But on the
other end, as politicians, we want to protect consumer interests as well.
If we increase, for instance, royalties, certainly they will transfer it to
their costs and the savings won't be there. We want to make sure that
whatever happens, we are coming with a fair balance. We think that we
have and we are close to having a very good package that will make sure
that this will happen.
We are not afraid of tough decisions. We are ready to make them,
but we want to make sure that our objectives will be met in the best
interests of the industry, for Canada and for Canadian consumers.
Vol. 11:19 1986
8
Canada-United States Law Journal, Vol. 11 [1986], Iss. , Art. 7
https://scholarlycommons.law.case.edu/cuslj/vol11/iss/7
